Discovery research	Pre-clinical research	IND-enabling development	Clinical development	Indication (Mechanism of Action)
KY1005 – Anti-OX40L				Immune-mediated diseases
KY1044 – Anti-ICOS agonist				T-cell activation
KY1043 – PD-L1 Immunocytokine				Novel biology
KY1081 – PD-L1 Immunocytokine				Novel biology
KY1055 – Anti-PD-L1xICOSbispecific mAb^2				Novel bispecific biology
KY1003 – Anti-PD-L1				Checkpoint inhibition and depletion
KY1007 – Anti CD7				Tumour-specific depletion
KY1041			MD Anderson Cancer Network™	T-cell activation
KY1051			HEPTARES therapeutics	GPCR target
KY1062			HEPTARES therapeutics	GPCR target
KY1070 – Anti-BMP6				Anaemia of chronic inflammation
KY1009				Haematology/vascular
KY1049				Haemophilia (Novel bispecific)
KY1066				Iron-loading anaemia
KY1060				Infectious diseases (antibody)
KV7009				Infectious diseases (antibody)
Anti-pertussis toxin			BILL & MELINDA GATES foundation	Infectious diseases (antibody)
Anti-Malaria			BILL & MELINDA GATES foundation	Infectious diseases (antibody)
Malaria & HIV Vaccines			BILL & MELINDA GATES foundation	Infectious diseases (vaccines)